Breaking News
ABM Industries Inc (ABM) Misses Q1 EPS Estimates
ABM Industries Inc (ABM) reported Q1 2026 gaap earnings of $0.83 per share, missing the $0.87 consensus estimate...
ADVERTISEMENT
Breaking News
Breaking market news, earnings coverage, and in-depth interviews with industry leaders.
Latest News
467 articles
Breaking News
Nio Inc (NIO) Beats Q4 EPS Estimates by a Wide Margin
Nio Inc (NIO) delivered Q4 2025 gaap earnings of $0.29 per share, surpassing analysts' $0.05 forecast (beat by...
Breaking News
Priority Technology Holdings, Inc (PRTH) Reports Q4 Earnings
Priority Technology Holdings, Inc (NASDAQ:PRTH) reported fourth quarter 2025 financial results. Q4 2025 adjusted earnings at Priority Technology...
Breaking News
Q32 Bio Inc. (QTTB) Reports Q4 Earnings
Q32 Bio Inc. (QTTB) reported Q4 2025 adjusted earnings of $3.65 per share. No consensus estimate was available...
Breaking News
Cullinan Therapeutics (CGEM) Reports Q4 Loss of $0.77 Per Share, Flat Year-Over-Year
Cullinan Therapeutics posts $0.73 per share loss in Q4 2025, matching year-ago results as the pre-revenue biotech maintains...
Breaking News
Tenax Therapeutics Inc (TENX) Reports Q4 Earnings
**Tenax Therapeutics Reports Q4 2025 Results**
Breaking News
Opus Genetics Inc. (IRD) Reports FY25 Earnings
**BREAKING: Opus Genetics Inc. Reports Q4 2025 Results**
Breaking News
Apyx Medical (APYX) Q4 Revenue Jumps 34.8% to $19.2M, Loss Narrows to $0.06/Share
Apyx Medical narrows Q4 loss to $0.06 per share as revenue surges 34.8% year-over-year to $19.2 million, with...
Breaking News
Cullinan Therapeutics Inc (CGEM) Reports Q4 Earnings
**Cullinan Therapeutics Inc Reports Q4 2025 Results**
Breaking News
Prelude Therapeutics Inc (PRLD) Reports Wider Loss for FY25 vs. Estimates
**BREAKING: Prelude Therapeutics Reports Wider-Than-Expected Q4 Loss**
Breaking News
Prelude Therapeutics (PRLD) Q4 Loss Widens 616.7% to $1.29/Share as Revenue Climbs to $12.1M
Prelude Therapeutics reports Q4 loss of $1.29/share, 616.7% wider than expected, despite revenue jumping to $12.1M from $6.5M...
Breaking News
Opus Genetics (IRD) Reports $0.80 Q4 Loss Despite 230% Revenue Surge to $14.2M
Opus Genetics posts $0.80 Q4 loss as revenue surges 230% year-over-year to $14.2M on collaboration activity.